About: Resveratrol and Copper for treatment of severe COVID-19: an observational study (RESCU 002)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Resveratrol and Copper for treatment of severe COVID-19: an observational study (RESCU 002) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Resveratrol and Copper for treatment of severe COVID-19: an observational study (RESCU 002)
Creator	Badwe, Rajendra Bhattacharjee, Atanu Chaturvedi, Pankaj Gota, Vikram Gupta, Sudeep Bhadade, Rakesh De Souza, Rosemarie Joshi, Mohan Madke, Tushar Mittra, Indraneel Qayyumi, Burhanuddin Shankpal, P
Source	MedRxiv
abstract	Background To be universally applicable in treatment of severe COVID-19, novel therapies, especially those with little toxicity and low cost, are urgently needed. We report here the use of one such therapeutic combination involving two commonly used nutraceuticals, namely resveratrol and copper in patients with this disease. This study was prompted by pre-clinical reports that sepsis-related cytokine storm and fatality in mice can be prevented by oral administration of small quantities of resveratrol and copper. Since cytokine storm and sepsis are major causes of death in severe COVID-19, we retrospectively analyzed outcomes of patients with this condition who had received resveratrol and copper. Methods & Findings Our analysis comprised of 230 patients with severe COVID-19 requiring inhaled oxygen who were admitted in a single tertiary care hospital in Mumbai between April 1 and May 13 2020. Thirty of these patients received, in addition to standard care, resveratrol and copper at doses of 5.6 mg and 560 ng, respectively, orally, once every 6 hours, until discharge or death. These doses were based on our pre-clinical studies, and were nearly 50 times and 2000 times less, respectively, than those recommended as health supplements. A multivariable-adjusted analysis was used to model the outcome of death in these patients and evaluate factors associated with this event. A binary logistic regression analysis was used, with age, sex, presence of comorbidities and receipt of resveratrol-copper as covariates. Data were updated as of May 30 2020. The number of deaths in resveratrol-copper and standard care only groups were 7/30 (23.3%, 95% CI 8.1%-38.4%) and 89/200 (44.5%, 95% CI 37.6%-51.3%), respectively. In multivariable analysis, age >50 years [odds ratio (OR) 2.558, 95% CI 1.454-4.302, P=0.0011] and female sex (OR 1.939, 95% CI 1.079-3.482, P=0.0267) were significantly associated, while presence of co-morbidities was not significantly associated (OR 0.713, 95% CI 0.405-1.256, P=0.2421) with death. There was a trend towards reduction in death in patients receiving resveratrol-copper (OR 0.413, 95% CI 0.164-1.039, P= 0.0604). Conclusions We provide preliminary results of a novel approach to the treatment of severe COVID-19 using a combination of small amounts of commonly used nutraceuticals, which is non-toxic and inexpensive, and therefore could be widely accessible globally. The nearly two-fold reduction in mortality with resveratrol-copper observed in our study needs to be confirmed in a randomized controlled trial.
has issue date	2020-07-29(xsd:dateTime)
bibo:doi	10.1101/2020.07.21.20151423
has license	medrxiv
sha1sum (hex)	d948da9c3b59203178b0e09e7602ef873e443904
schema:url	https://doi.org/10.1101/2020.07.21.20151423
resource representing a document's title	Resveratrol and Copper for treatment of severe COVID-19: an observational study (RESCU 002)
resource representing a document's body	covid:d948da9c3b59203178b0e09e7602ef873e443904#body_text
is schema:about of	named entity 'severe' named entity 'RESCU' named entity 'APPLICABLE' named entity 'REPORT' covid:arg/d948da9c3b59203178b0e09e7602ef873e443904 named entity 'commonly' named entity 'resveratrol' named entity 'universally' named entity 'mice' named entity 'needed' named entity 'quantities' named entity 'received' named entity 'copper' named entity 'Copper' named entity 'copper' named entity 'cytokine storm' named entity 'Copper' named entity 'observational study' named entity 'COVID-19' named entity 'preclinical' named entity 'standard of care' named entity 'India' named entity 'genomes' named entity 'peer review' named entity 'dyspnea' named entity 'retrospective study' named entity 'vicious cycle' named entity 'resveratrol' named entity 'inflammation' named entity 'copper' named entity 'DNA double-strand breaks' named entity 'randomized clinical trial' named entity 'oxygen' named entity 'peer review' named entity 'peer review' named entity 'water-based solution' named entity 'copper' named entity 'resveratrol' named entity 'Diabetes' named entity 'Trans-resveratrol' named entity 'SARS-COV-2' named entity 'resveratrol' named entity 'free-radicals' named entity 'cytokine storm' named entity 'resveratrol' named entity 'unfractionated heparin' named entity 'chromatin' named entity 'pre-clinical studies' named entity 'copper' named entity 'resveratrol' named entity 'chromatin' named entity 'anti-oxidant' named entity 'Government of India' named entity 'nutraceuticals' named entity 'copper' named entity 'oral administration' named entity 'unfractionated heparin' named entity 'confounding' named entity 'Department of Atomic Energy' named entity 'injectable' named entity 'chi-square test' named entity 'renal dialysis' named entity 'sepsis' named entity 'oxygen' named entity 'host cells' named entity 'copper' named entity 'control groups' named entity 'medRxiv' named entity 'anticoagulation' named entity 'medRxiv' named entity 'infection' named entity 'vitamin' named entity 'Mumbai' named entity 'intubated'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software